SI — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-13

• We believe the shoulder surgical care market today presents a significant market opportunity. Our initial focus within this broader market is on shoulder arthroplasty. Shoulder arthroplasty is an established surgical procedure involving the reconstruction of the shoulder joint with prosthetic implan…

• •Continued investments in product development, innovation and growth. We expect to continue to focus on long-term revenue growth through investments in our ecosystem and expansion of our operations. In research and development, we continually invest in improving our technologies, developing new prod…

• including with respect to our supporting technologies, in order to further bolster our ecosystem. While research and development are time consuming and costly and therefore negatively impact our results of operations in the near term, we believe expanding into new areas, implementing product improve…

• •Reimbursement and coverage. Healthcare providers generally rely on third-party payors, including federal Medicare, state Medicaid and private health insurance plans, to cover and reimburse all or part of the cost of our implant systems. As a result, demand for our implant systems depends in large p…

• costs of other services. We expect our gross margin to remain consistent for the foreseeable future as our net revenue grows and our related costs of goods sold increases.

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• We believe the shoulder surgical care market today presents a significant market opportunity. Our initial focus within this broader market is on shoulder arthroplasty, and we developed our ecosystem with an approach to innovation that prioritizes ease of use, flexibility, predictability of outcomes …

• •Continued investments in product development, innovation and growth. We expect to continue to focus on long-term revenue growth through investments in our ecosystem and expansion of our operations. In research and development, we continually invest in improving our technologies, developing new prod…

• •Reimbursement and coverage. Healthcare providers generally rely on third-party payors, including federal Medicare, state Medicaid and private health insurance plans, to cover and reimburse all or part of the cost of our implant systems. As a result, demand for our implant systems depends in large p…

• outpatient settings. Effective as of January 1, 2024, Centers for Medicare and Medicaid Services (“CMS”) added total shoulder arthroplasty to the ASC covered procedures list, which allows procedures that use our implant systems to be performed at ASCs and be reimbursed by Medicare. We believe this d…

• design surgeons, royalty payments made pursuant to our License Agreement (as defined below), travel expenses, professional services fees (including consulting, legal, finance, audit and tax fees), insurance costs, allocated facility expenses and other general corporate expenses.

Text added vs the prior filing · source: 10-Q · 2026-05-13

• Investing in our common stock involves a high degree of risk. Risk factors describing the major risks to our business can be found under Part I, Item 1A, “Risk Factors” in the Company’s 2025 Annual Report. You should consider carefully the risks and uncertainties described therein, together with all…

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• Our business involves a high degree of risk. You should carefully consider each of the following risk factors and all other information set forth in this Quarterly Report on Form 10-Q and our other filings with the SEC. The risks and uncertainties described below are not the only ones we face. If an…

• Risks Related to Our Financial Condition and Capital Requirements

• We are an early-stage company with a history of significant net losses, we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.

• We have incurred annual net losses since our inception, and we expect to incur additional substantial losses in the foreseeable future. For the nine months ended September 30, 2025 and 2024, we had a net loss of $32,587 thousand and $11,827 thousand, respectively. As of September 30, 2025, we had an…

• If we fail to manage our growth effectively, our business could be materially and adversely affected.

Text added vs the prior filing · source: 10-Q · 2026-05-13

• On March 13, 2026, Matthew Ahearn, Chief Operating Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c), to sell up to 67,500 shares of our common stock between March 13, 2026 and February 15, 2027, subject to certain conditions.

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• During the three months ended September 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.